Connection

CHRISTIE BALLANTYNE to Hyperlipidemias

This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Hyperlipidemias.
Connection Strength

5.266
  1. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):899-912.
    View in: PubMed
    Score: 0.819
  2. Severe hypercholesterolemia in a patient with very low albumin and normal renal function. J Clin Lipidol. 2023 Jan-Feb; 17(1):64-67.
    View in: PubMed
    Score: 0.735
  3. Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? Eur J Prev Cardiol. 2021 03 23; 28(1):30-32.
    View in: PubMed
    Score: 0.657
  4. Genetic testing in hyperlipidemia. Cardiol Clin. 2015 May; 33(2):267-75.
    View in: PubMed
    Score: 0.436
  5. Lipids and CVD management: towards a global consensus. Eur Heart J. 2005 Nov; 26(21):2224-31.
    View in: PubMed
    Score: 0.220
  6. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):913-925.
    View in: PubMed
    Score: 0.205
  7. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003 Oct 27; 163(19):2394-5.
    View in: PubMed
    Score: 0.196
  8. Primary Prevention Management of Elevated Lipoprotein(a). JAMA Cardiol. 2023 01 01; 8(1):96-97.
    View in: PubMed
    Score: 0.186
  9. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002 Nov 20; 90(10B):21K-29K.
    View in: PubMed
    Score: 0.184
  10. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):617-625.
    View in: PubMed
    Score: 0.179
  11. Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr-/- Mice. Cells. 2022 05 30; 11(11).
    View in: PubMed
    Score: 0.178
  12. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
    View in: PubMed
    Score: 0.174
  13. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol. 1997 Mar; 12(2):153-60.
    View in: PubMed
    Score: 0.124
  14. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 1996 Sep 01; 78(5):532-5.
    View in: PubMed
    Score: 0.120
  15. Postprandial effects on arterial stiffness parameters in healthy young adults. Vasc Med. 2015 Dec; 20(6):501-8.
    View in: PubMed
    Score: 0.110
  16. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
    View in: PubMed
    Score: 0.101
  17. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992 May; 19(6):1315-21.
    View in: PubMed
    Score: 0.089
  18. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
    View in: PubMed
    Score: 0.077
  19. Inflammation, adipose tissue, and T cells: what is the "straight skinny" on lean versus fat mice? Circ Res. 2009 Jul 17; 105(2):e3-4; author reply e5.
    View in: PubMed
    Score: 0.073
  20. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
    View in: PubMed
    Score: 0.064
  21. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials. 2006 Dec; 27(6):518-30.
    View in: PubMed
    Score: 0.059
  22. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar; 259(3):247-58.
    View in: PubMed
    Score: 0.058
  23. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006 Mar-Apr; 12(2):159-64.
    View in: PubMed
    Score: 0.058
  24. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Am J Cardiol. 2005 Feb 01; 95(3):367-72.
    View in: PubMed
    Score: 0.054
  25. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.047
  26. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.022
  27. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
    View in: PubMed
    Score: 0.017
  28. Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA. 2005 Sep 07; 294(9):1043-51.
    View in: PubMed
    Score: 0.014
  29. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation. 2001 Oct 15; 72(7):1244-50.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.